Dr. Kossi Kwame Amouzou

Dr. Kossi Kwame Amouzou is a dermatologist practicing at the Centre Hospitalier Universitaire (CHU) Sylvanus Olympio in Lomé — Togo's largest public teaching hospital and principal academic medical center, affiliated with the Université de Lomé. With over 15 years of clinical experience, Dr. Amouzou addresses the dermatological needs of Togo's population, which faces a significant burden of tropical skin diseases including onchocerciasis (river blindness), mycetoma, leprosy, and a high prevalence of skin infections exacerbated by the humid West African climate. He provides specialist dermatological care within the hospital's outpatient and inpatient services, managing both common dermatoses and the complex skin manifestations of HIV/AIDS, which remains a significant public health concern in Togo. He is also involved in training medical students and residents at the university-affiliated hospital, contributing to the expansion of Togo's dermatology workforce.

Dr. Amouzou completed his medical training at the Université de Lomé's Faculté des Sciences de la Santé — Togo's primary medical school. He earned his MD and subsequently pursued specialist postgraduate training, obtaining the Diplôme d'Études Spécialisées (DES) in Dermatologie-Vénéréologie — the French-system specialist qualification covering both dermatology and venereology (sexually transmitted infections). This combination reflects the African medical training tradition of treating skin and STI services as integrated specialties. He also obtained certification in Tropical Dermatology through West African regional training programs that address the specific dermatological disease profile of the ECOWAS region. His training in both French and English-language medical literature gives him access to international evidence-based dermatological guidelines.

Dr. Amouzou's dermatological practice reflects the disease burden of sub-Saharan West Africa. His tropical dermatology expertise encompasses the diagnosis and management of fungal infections (tinea species, pityriasis versicolor), parasitic infestations (scabies, cutaneous larva migrans, myiasis), bacterial skin infections, and the skin manifestations of neglected tropical diseases including leprosy and Buruli ulcer. In sexually transmitted dermatology, he manages syphilis, gonorrhea, genital herpes, and the cutaneous manifestations of HIV including Kaposi's sarcoma, extensive molluscum contagiosum, and seborrheic dermatitis associated with immunosuppression. Skin cancer screening — particularly for melanoma and squamous cell carcinoma — is a growing focus given Togo's increasing UV exposure and changing demographics. He also manages common inflammatory dermatoses including eczema, psoriasis, and acne.

CHU Sylvanus Olympio is Togo's principal referral hospital and serves expatriate communities, NGO workers, and international visitors in Lomé. The hospital's dermatology department is accessible to international patients, and consultations can be arranged through the hospital's outpatient registration system. Lomé is a regional commercial hub with good air connectivity to Paris, Brussels, Casablanca, and other African capitals, making it accessible for medical visits from francophone West Africa. Patients requiring advanced diagnostic procedures such as dermoscopy or Mohs micrographic surgery may be referred to more specialized centers in Abidjan (Côte d'Ivoire), Dakar (Senegal), or Paris, France, through established referral networks. Dr. Amouzou communicates in French and has working knowledge of English.

Dr. Amouzou has been recognized for his contribution to dermatological care and education at Togo's leading teaching hospital. His participation in West African regional dermatology networks and tropical medicine symposia reflects peer recognition across the ECOWAS medical community. As a university-affiliated clinician at CHU Sylvanus Olympio, his teaching and mentorship of medical students and junior residents represents a sustained contribution to medical capacity building in Togo. His involvement in national skin disease surveillance programs — including leprosy elimination monitoring and Buruli ulcer detection — demonstrates alignment with international public health priorities.